BiotechTube

FIB Grifols

Phase 3Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Congenital Afibrinogenemia

Conditions

Congenital Afibrinogenemia, Hypofibrinogenemia

Trial Timeline

Dec 1, 2023 → Mar 1, 2025

NCT ID
NCT04636268

About FIB Grifols

FIB Grifols is a phase 3 stage product being developed by Grifols for Congenital Afibrinogenemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04636268. Target conditions include Congenital Afibrinogenemia, Hypofibrinogenemia.

What happened to similar drugs?

5 of 20 similar drugs in Congenital Afibrinogenemia were approved

Approved (5) Terminated (0) Active (15)
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved
✅activated recombinant human factor VII + activated recombinant human factor VII + factor VIIINovo NordiskApproved
✅Lipiodol Ultra Fluid with surgical gluesGuerbetApproved
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
🔄turoctocog alfa pegolNovo NordiskPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04636268Phase 3Withdrawn

Competing Products

20 competing products in Congenital Afibrinogenemia

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
KW-3357Kyowa KirinPhase 1
29
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
27
Sandostatine LPNovartisPhase 2
35
mycophenolate mofetilRochePhase 1
29
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29
Advate® + turoctocog alfaNovo NordiskPhase 1
29